ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -37 مورد

Management of treatment interruptions* table

Management of treatment interruptions* table
Time point of interruption Details of interruption Approach
During intensive phase
  • Lapse is <14 days in duration
  • Continue treatment to complete planned total number of doses (as long as all doses are completed within 3 months)
  • Lapse is ≥14 days in duration
  • Restart treatment from the beginning
During continuation phase
  • Received ≥80% of doses and sputum was AFB smear negative on initial testing
  • Further therapy may not be necessary
  • Received ≥80% of doses and sputum was AFB smear positive on initial testing
  • Continue therapy until all doses are completed
  • Received <80% of doses and accumulative lapse is <3 months in duration
  • Continue therapy until all doses are completed (full course), unless consecutive lapse is >2 months
  • If treatment cannot be completed within recommended time frame for regimen, restart therapy from the beginning (ie, restart intensive phase, to be followed by continuation phase)
  • Received <80% of doses and lapse is ≥3 months in duration
  • Restart therapy from the beginning, new intensive and continuation phases (ie, restart intensive phase, to be followed by continuation phase)

AFB: acid-fast bacilli.

* According to expert opinion, patients who are lost to follow-up (on treatment) and brought back to therapy, with interim treatment interruption, should have sputum resent for AFB smear, culture, and drug susceptibility testing.

¶ The recommended time frame for regimen, in tuberculosis control programs in the United States and in several European countries, is to administer all of the specified number of doses for the intensive phase within 3 months and those for the 4-month continuation phase within 6 months, so that the 6-month regimen is completed within 9 months.
Reproduced from: Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 63(7):e147-e195. doi: 10.1093/cid/ciw376. Reprinted by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright © 2016. https://www.idsociety.org/practice-guideline/treatment-of-drug-susceptible-tb/.
Graphic 109491 Version 18.0